Strategic National Stockpile: What It Holds and How It Deploys

The Strategic National Stockpile (SNS) is the US federal reserve of medicines, vaccines and medical supplies for public health emergencies, managed by the Administration for Strategic Preparedness and Response (ASPR) within HHS. It exists mainly for products that are not commercially available, and it acts as a safety net once state and local resources are exhausted. This page is general information, not medical advice.

Short answer

The SNS holds large quantities of emergency medicines, vaccines and other medical supplies for chemical, biological, radiological and nuclear incidents, pandemics and emerging infectious diseases. States, localities, tribes and territories request it through HHS; it is a federal backstop, not a replacement for a facility’s own supply planning.

Definition and scope

ASPR describes the SNS as a critical part of the federal medical response infrastructure. The Center for the SNS within ASPR runs it. According to the Congressional Research Service (CRS report R47400, 26 September 2023), Congress established it through P.L. 107-188 (2002), and it is governed by 42 U.S.C. 247d-6b. It holds drugs, vaccines, medical products and ancillary supplies.

ASPR lists these formulary categories: antibiotics and antivirals; vaccines; chemical nerve agent antidotes and antitoxins; radiological chelators, thyroid blockers and anti-neutropenics; IV fluids, IV ancillary and airway management supplies; burn and blast supplies; ventilators; and personal protective equipment (PPE). CRS names masks, gowns, gloves, N-95 respirators and face shields among the PPE.

How a request and deployment work

CRS reports that the statute does not require a declared public health emergency before a request. A jurisdiction first works with its ASPR Regional Emergency Coordinator, then submits a request to the HHS Secretary’s Operations Center. ASPR fully fills, partially fills or denies it. Tribes may request through their state health office or the Indian Health Service.

The receiving jurisdiction needs plans to receive, store and distribute the supplies, and bears costs while the supplies are in its possession (CRS R47400).

Inventory and delivery tiers compared

The stockpile is not one warehouse shipment. CRS describes several delivery arrangements, summarised here from that report.

Tier	What CRS says
Push packages	Prepackaged and transport-ready; can reach anywhere in the US or territories within 12 hours of the decision to deploy; under 5% of contents; the whole package is sent even if some items are not needed.
SNS-managed inventory	The majority of the stockpile’s supplies, held in undisclosed warehouses.
Vendor-managed inventory	Vendors store and rotate product; delivery in 24 to 36 hours. HHS ended all such contracts in 2017 and began reissuing them during COVID-19; about 10% of current contracts.
User-managed inventory	Pre-positioned caches such as CHEMPACKs, at more than 1,340 locations.

CRS also lists predetermined packages such as CHEMPACKs and Federal Medical Stations.

How stock is maintained

ASPR states that it applies quality assurance to all products, takes an annual inventory, oversees shelf life to stay within FDA potency limits, and inspects environmental conditions, security and package integrity. Eligible near-expiry products may enter the Federal Shelf Life Extension Program (SLEP) for FDA review: ASPR says initial testing typically extends shelf life 12 to 24 months and failed lots are removed. The SNS stopped relabeling extended products in 2012; new dates are published through Dear Healthcare Provider letters or the ASPR website. See our guide to the Shelf Life Extension Program.

Where it matters for labs, clinics and supply decisions

• CRS reports that no law requires state, local, tribal or territorial governments to keep their own stockpiles; a 2023 pilot supports states that choose to.
• CRS notes the stockpile has finite resources and that tribal access problems were reported during COVID-19.
• Receipt, storage and distribution planning sit with the requesting jurisdiction, so a facility’s own inventory and distributor arrangements remain part of its preparedness picture.

For how stockpiles sit within wider supply chains, see medical supply logistics, PPE stockpile and surge demand planning, disaster relief medical supply cache planning and emergency preparedness.

History: from the National Pharmaceutical Stockpile to ASPR

CRS traces the program through several statutory steps.

• 1999: Congress directed the CDC to create a pharmaceutical and vaccine stockpile, first named the National Pharmaceutical Stockpile (P.L. 105-277).
• 2002: The Public Health Security and Bioterrorism Preparedness and Response Act (P.L. 107-188) renamed it the Strategic National Stockpile. The Homeland Security Act of 2002 moved it to the Department of Homeland Security.
• 2004: The Project BioShield Act (P.L. 108-276) moved it back to HHS, under the CDC.
• 2018: ASPR, which P.L. 113-5 had given coordination authority, took operational control. In July 2022 ASPR was renamed the Administration for Strategic Preparedness and Response.

ASPR says the Center for the SNS has more than 250 civil servants, US Public Health Service officers and contractors, with expertise that includes medical logistics, quality control, procurement and financial management.

How the stockpile is stocked and funded

The governing statute, 42 U.S.C. 247d-6b(a), directs the HHS Secretary to maintain stockpiles of drugs, vaccines, biological products, medical devices and other supplies, including personal protective equipment and ancillary medical supplies, in amounts the Secretary considers appropriate. The same subsection sets several rules that shape what is added or replaced:

• An annual threat-based review of stockpile contents, done in consultation with the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) and submitted to Congress each March 15.
• Each annual review must, for every new, modified or replacement countermeasure procurement, report the quantities, supply chain, the presence or lack of a commercial market, and the threat it addresses.
• Products receive equal consideration whether or not they received advanced research and development funding.
• Procedures for inventory, accounting and physical security, plus regular review and revision of contents, including disposal of items no longer usable.
• Technical assistance to state, local and tribal capabilities to distribute and dispense stockpile products, and at least one stakeholder meeting a year.

CRS describes two funding streams. Regular appropriations, through the Public Health and Social Services Emergency Fund, pay for items that exist on the commercial market, such as syringes, bandages, respirators and ciprofloxacin. Project BioShield pays for countermeasures that the commercial market cannot supply, and a drug bought this way can enter the stockpile before FDA approval. CRS lists SNS appropriations of 51.0 million dollars in FY1999, 645.0 million in FY2002, 705.0 million in FY2021, 845.0 million in FY2022 and 965.0 million in FY2023, excluding emergency supplementals (nominal dollars, CRS Table 1).

What the oversight record says

GAO (GAO-23-106210, 17 October 2022) found that HHS’s annual inventory reviews for fiscal years 2020 through 2022 were not completed after an expert group was reorganized, and that reviews for fiscal years 2023 and 2024 did not meet most statutory requirements because procedures had not been updated after 2019 legislation. GAO also found the stockpile held most recommended countermeasure types, but often not in the recommended quantities, which HHS attributed to budget constraints. Smallpox and anthrax countermeasures accounted for roughly 75% of non-COVID-19 obligations in FY2015 to FY2021 (CRS, citing GAO). GAO made three recommendations, HHS concurred, and GAO lists all three as closed and implemented, with ASPR finalizing updated review procedures in June 2024.

What COVID-19 changed in the inventory

GAO reports that HHS obligated 6.1 billion dollars of COVID-19 relief funds for stockpile supplies and that most of it went to ventilators and personal protective equipment, substantially increasing those items relative to pre-pandemic levels and adding new product types such as sedatives used with ventilators and testing supplies. CRS reports that HHS had obligated about 10.5 billion of a planned 13.9 billion dollars for the SNS as of February 2022 (citing GAO), and that tribes, tribal organizations and urban Indian organizations reported difficulties accessing the stockpile during the pandemic.

Where the stockpile sits relative to a facility’s own supply chain

The stockpile is not an ordering channel for individual hospitals, clinics or laboratories. A request comes from a state, local, tribal or territorial jurisdiction through HHS, and the commercial items CRS describes as funded by regular appropriations (syringes, bandages, respirators) are the same categories facilities manage through their own distributors. ASPR states that the SNS works as a backup when state and local resources run out or when critical products are not available commercially. For related topics, see the Hospital Preparedness Program, Disaster Medical Assistance Teams, and how to read a lot number for tracking product lots and dates.

Common misunderstandings

• “It is just ordinary supplies in bulk.” ASPR says many of its products are not commercially available.
• “It needs a declared emergency.” CRS says the statute does not require a public health emergency declaration for a request.
• “Everything ships in 12 hours.” The 12-hour figure applies to push packages, under 5% of contents; vendor-managed inventory is described at 24 to 36 hours.
• “Local governments must hold their own share.” No law requires it, per CRS.

FAQ

Who manages the Strategic National Stockpile?

The Center for the SNS within ASPR, part of HHS.

What is in the Strategic National Stockpile?

Antibiotics, antivirals, vaccines, antidotes and antitoxins, radiological countermeasures, IV and airway supplies, burn and blast supplies, ventilators and PPE, per ASPR’s inventory overview. Current stock levels are not published here.

Who can request it?

States, localities, tribes and territories, at the HHS Secretary’s discretion, via the process above.

When was the Strategic National Stockpile created?

Congress directed the CDC to create it in 1999 as the National Pharmaceutical Stockpile; the 2002 Bioterrorism Preparedness and Response Act renamed it the Strategic National Stockpile (CRS R47400).

Where are the stockpile warehouses?

CRS reports that SNS-managed inventory is held in multiple warehouses across the United States and that the locations are not publicly available.

How is the stockpile funded and restocked?

Through annual appropriations for commercially available items and through Project BioShield for countermeasures the commercial market cannot supply, with an annual threat-based review of contents reported to Congress under 42 U.S.C. 247d-6b.

Can a hospital or laboratory order directly from the stockpile?

No direct ordering route is described in the sources; requests come from state, local, tribal or territorial jurisdictions through HHS.

Sources

• ASPR, SNS Inventory Overview, checked 30 October 2026.
• ASPR, Center for the Strategic National Stockpile, checked 30 October 2026.
• Congressional Research Service, R47400, The Strategic National Stockpile: Overview and Issues for Congress, 26 September 2023, checked 30 October 2026.
• Government Accountability Office, GAO-23-106210, Public Health Preparedness: HHS Should Address Strategic National Stockpile Requirements and Inventory Risks, 17 October 2022, checked 2026-10-30.
• Legal Information Institute, 42 U.S.C. 247d-6b, Procurement and Stockpiling, checked 2026-10-30.
• ASPR, SNS Who We Are, checked 2026-10-30.